- Home
- PRTG vs THAR Comparison
PRTG vs THAR Comparison
Compare PRTG & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTG
- THAR
- Stock Information
- Founded
- PRTG 1973
- THAR 2017
- Country
- PRTG British Virgin Islands
- THAR United States
- Employees
- PRTG N/A
- THAR N/A
- Industry
- PRTG Oil & Gas Production
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- PRTG Energy
- THAR Health Care
- Exchange
- PRTG Nasdaq
- THAR Nasdaq
- Market Cap
- PRTG 4.7M
- THAR 4.0M
- IPO Year
- PRTG N/A
- THAR 2022
- Fundamental
- Price
- PRTG $4.00
- THAR $2.16
- Analyst Decision
- PRTG
- THAR Strong Buy
- Analyst Count
- PRTG 0
- THAR 1
- Target Price
- PRTG N/A
- THAR $17.00
- AVG Volume (30 Days)
- PRTG 65.1K
- THAR 53.4K
- Earning Date
- PRTG 02-26-2025
- THAR 11-07-2024
- Dividend Yield
- PRTG N/A
- THAR N/A
- EPS Growth
- PRTG N/A
- THAR N/A
- EPS
- PRTG N/A
- THAR N/A
- Revenue
- PRTG N/A
- THAR N/A
- Revenue This Year
- PRTG N/A
- THAR N/A
- Revenue Next Year
- PRTG N/A
- THAR N/A
- P/E Ratio
- PRTG N/A
- THAR N/A
- Revenue Growth
- PRTG N/A
- THAR N/A
- 52 Week Low
- PRTG $2.10
- THAR $1.84
- 52 Week High
- PRTG $23.01
- THAR $7.71
- Technical
- Relative Strength Index (RSI)
- PRTG 41.86
- THAR 53.22
- Support Level
- PRTG $3.86
- THAR $1.96
- Resistance Level
- PRTG $4.40
- THAR $2.11
- Average True Range (ATR)
- PRTG 0.45
- THAR 0.12
- MACD
- PRTG -0.09
- THAR 0.01
- Stochastic Oscillator
- PRTG 11.11
- THAR 68.18
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.